Tadano Y, et al. - In real-world percutaneous coronary intervention (PCI) patients, researchers assessed the 1-year clinical outcomes after bioresorbable polymer sirolimus-eluting Ultimaster stent (BP-SES) implantation, as well as predictors of adverse outcomes in this single-center, all-comers study. A total of 1,727 patients had BP-SESs implanted; 67% were men, the mean age was 72 years, and 37% had diabetes. A total of 2,085 lesions were detected. Type B2/C lesions, chronic total occlusions (CTOs), and bifurcations constituted 88%, 4%, and 23% of them, respectively. At 1-year, 2.4% and 5.2% cumulative incidences of target lesion revascularization and target lesion failure, respectively, were reported. Adverse clinical outcomes after BP-SES implantation were more likely to develop in patients on hemodialysis (HD) and those with CTO. No significant association of small vessel diameter with adverse outcomes was observed. Among all-comer PCI cases, including patients receiving HD and those with in-stent restenosis, favorable 1-year clinical outcomes after BP-SES implantation were observed.